These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9490144)

  • 1. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness and tolerance of three month sustained release leuprorelin in the treatment of metastatic prostatic cancer (comparative, randomized, multicentric study].
    Zerbib M; Lucas C; Leblanc V
    Prog Urol; 1997 Apr; 7(2):246-53. PubMed ID: 9264767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eligard: leuprolide acetate in a novel sustained-release delivery system.
    Sartor O
    Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer.
    Kuhn JM; Abourachid H; Brucher P; Doutres JC; Fretin J; Jaupitre A; Jorest R; Lambert D; Petit J; Pin J; Blumberg J; Dufour-Esquerré F
    Eur Urol; 1997; 32(4):397-403. PubMed ID: 9412795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
    Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
    Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open, multi-center, phase IV study to assess the efficacy and tolerability of triptorelin in Taiwanese patients with advanced prostate cancer.
    Kao CC; Chang YH; Wu T; Sun GH; Yu DS; Chang SY; Cha TL
    J Chin Med Assoc; 2012 Jun; 75(6):255-61. PubMed ID: 22721619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
    Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
    J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
    Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
    Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
    Spitz A; Young JM; Larsen L; Mattia-Goldberg C; Donnelly J; Chwalisz K
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):93-9. PubMed ID: 22025196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
    Lundström EA; Rencken RK; van Wyk JH; Coetzee LJ; Bahlmann JC; Reif S; Strasheim EA; Bigalke MC; Pontin AR; Goedhals L; Steyn DG; Heyns CF; Aldera LA; Mackenzie TM; Purcea D; Grosgurin PY; Porchet HC
    Clin Drug Investig; 2009; 29(12):757-65. PubMed ID: 19888782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen-all that rises is not refractory.
    Hintz BL; Van Nieuwenhuize A; Kagan AR
    Urology; 2001 May; 57(5):975. PubMed ID: 11337308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.